Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Sino Biopharmaceutical Limited
  6. News
  7. Summary
    1177   KYG8167W1380

SINO BIOPHARMACEUTICAL LIMITED

(1177)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sino Biopharmaceutical Limited Announces Approval for the First Generic "Colistimethate Sodium for Injection" for Marketing

10/15/2021 | 06:44am EST

The board of directors of Sino Biopharmaceutical Limited announced that, "Colistimethate Sodium for Injection" (Brand name: Tianyun), an anti-infective drug developed by the Group, has obtained drug registration certificate granted by the National Medical Products Administration of the PRC. The product was filed as a Chemicals Category 3 drug and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs, being the first generic drug of its kind that has been approved for marketing in the PRC. The approved indications of Colistimethate Sodium for Injection developed by the Group include: the treatment of acute or chronic infections caused by susceptible strains of sensitive Gram-negative bacilli, especially those caused by susceptible strains of Pseudomonas aeruginosa and Acinetobacter baumannii; it can also be used for the initial treatment of serious infections suspected to be caused by Gram- negative bacteria and the treatment of infections caused by sensitive Gram-negative bacilli. In addition, the active pharmaceutical ingredient ("API") of Colistimethate Sodium is self-produced by the Group, which has obtained the Certification of Suitability to the Monographs of the European Pharmacopoeia ("CEP") issued by the European Directorate for the Quality of Medicines and HealthCare ("EDQM"), and has been successively sold to Spain and other European countries. The CEP is one of the quality certifications for APIs with the highest standard in the world. Obtaining this certification indicates that the processing technology for manufacturing the relevant API has reached the international advanced standard. The approval of the Colistimethate Sodium product for marketing in the PRC will help the Group accelerate the pace of internationalization and facilitate its deployment in overseas markets.


ę S&P Capital IQ 2021
All news about SINO BIOPHARMACEUTICAL LIMITED
12/01Sino Biopharmaceutical Limited Enters into A Facility Agreement
CI
11/18Treadwell Therapeutics Inc. announced that it has received $91 million in funding from ..
CI
11/08Sino Biopharmaceutical Repurchases 5 Million Shares
MT
11/03Sino Biopharm Repurchases 3.5 Million Shares
MT
11/03Sino Biopharmaceutical Buys Back 1.7 Million Shares
MT
10/18SINO BIOPHARMACEUTICAL : Biopharm's Antibiotic Wins Marketing Approval in China
MT
10/15Sino Biopharmaceutical Limited Announces Approval for the First Generic "Colistimethate..
CI
10/08SINO BIOPHARMACEUTICAL : Anti-Tumor Drug Registration Accepted in China
MT
10/08SINO BIOPHARMACEUTICAL : Gets US FDA Nod for Clinical Trial of Cough, Pain Treatment
MT
10/08Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine "Tcr167..
CI
More news
Analyst Recommendations on SINO BIOPHARMACEUTICAL LIMITED
More recommendations
Financials
Sales 2021 34 160 M 4 383 M 4 383 M
Net income 2021 11 001 M 1 411 M 1 411 M
Net cash 2021 11 702 M 1 502 M 1 502 M
P/E ratio 2021 10,6x
Yield 2021 2,35%
Capitalization 107 B 13 718 M 13 719 M
EV / Sales 2021 2,79x
EV / Sales 2022 2,23x
Nbr of Employees 24 443
Free-Float 52,2%
Chart SINO BIOPHARMACEUTICAL LIMITED
Duration : Period :
Sino Biopharmaceutical Limited Technical Analysis Chart | 1177 | KYG8167W1380 | MarketScreener
Technical analysis trends SINO BIOPHARMACEUTICAL LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 5,70 HKD
Average target price 10,57 HKD
Spread / Average Target 85,4%
EPS Revisions
Managers and Directors
Yi Li Chief Executive Officer & Executive Director
Theresa Tse Chairman
Hsuan Tse General Manager-Information Management
Wei Nong Ye General Manager-Research & Development
Mao Li Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
SINO BIOPHARMACEUTICAL LIMITED-24.00%13 718
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641